Context: The Orphan Drug Act incentivizes medication development for rare diseases, offering substantial financial benefits to the manufacturer. Orphan products constitute most new drug approvals in oncology, but safety and efficacy questions have emerged about some of these agents. Objectives: To define characteristics of orphan cancer drugs and their pivotal clinical trials and to compare these with nonorphan drugs. Design and Setting: We identified all new orphan and nonorphan drugs approved between 2004 and 2010 to treat cancer. We then collected data on key development variables from publicly available information on the US Food and Drug Administration's Web site and in the Code of Federal Regulations. Main Outcome Measures: We assessed clinical testing dates, approved indications, and regulatory characteristics (regular vs accelerated review, advisory committee review, postmarketing commitments). We then compared design features (randomization, blinding, primary end point) of pivotal trials supporting approval of orphan and nonorphan drugs and rates of adverse safety outcomes (deaths not attributed to disease progression, serious adverse events, dropouts) in pivotal trials. Results: Fifteen orphan and 12 nonorphan drugs were approved between January 1, 2004, and December 31, 2010. Pivotal trials of orphan drugs had smaller participant numbers (median, 96 [interquartile range {IQR}, 66-152] vs 290 [IQR, 185-394] patients exposed to the drug; P
CITATION STYLE
Kesselheim, A. S., Myers, J. A., & Avorn, J. (2011). Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA, 305(22), 2320–2326. https://doi.org/10.1001/jama.2011.769
Mendeley helps you to discover research relevant for your work.